Betnovate Scalp Application Dosage

Did you have any side effects with this medicine?
sponsored

Dosage of Betnovate Scalp Application in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Dosing requirements are variable and must be individualized on the basis of the specific disease, its severity and the response of the patient.

The initial dose should be maintained or adjusted until a satisfactory response is observed. If a satisfactory clinical response does not occur after a reasonable period of time, treatment with Betnovate Scalp Application injection should be discontinued and other appropriate therapy initiated.

Systemic Administration: For systemic therapy, treatment is initiated with 1-2 mL in most conditions and repeated as necessary. Administration is by deep intramuscular (IM) injection in the gluteal region. Dosage and frequency of administration will depend on the severity of the patient's condition and the therapeutic response. Two mL might be required initially in a severe illness eg, lupus erythematosus or status asthmaticus which has been resolved by appropriate life-saving procedures.

A wide variety of dermatologic conditions respond effectively to an IM injection of 1 mL Betnovate Scalp Application injection, repeated according to the response of the condition.

In respiratory tract disorders, onset of relief from symptoms has occurred within a few hours after IM injection of Betnovate Scalp Application. Effective control of symptoms with 1-2 mL is obtained in bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis.

Treatment of Acute or Chronic Bursitis: Results are obtained with 1-2 mL IM injection of Betnovate Scalp Application injection, repeated as necessary.

Local Administration: Concomitant use of a local anesthetic is rarely necessary. If co-administration of a local anesthetic is desired, Betnovate Scalp Application injection may be mixed (in the syringe, not the vial) with 1 or 2% procaine HCl or lidocaine, using formulations which do not contain parabens. Similar local anesthetics may also be used. Anesthetics containing methylparaben, propylparaben, phenol, and others, should be avoided. The required dose of Betnovate Scalp Application injection is first withdrawn from the vial into the syringe. The local anesthetic is then drawn in, and the syringe is shaken briefly.

In acute subdeltoid, subacromial, olecranon, and prepatellar bursitis, an intrabursal injection of 1-2 mL of Betnovate Scalp Application may relieve pain and restore full range of movement within a few hours. Chronic bursitis may be treated with reduced dosage once acute symptoms are controlled. In acute tenosynovitis, tendinitis and peritendinitis, 1 injection of Betnovate Scalp Application should alleviate the condition. In chronic forms of these conditions, it may be necessary to repeat the injection as the patient's condition requires.

Following 0.5-2 mL intra-articular administration of Betnovate Scalp Application injection, relief from pain, soreness and stiffness associated with rheumatoid arthritis and osteoarthritis may be experienced within 2-4 hrs. Duration of relief, which varies widely in both diseases, is ≥4 weeks in the majority of cases.

An intra-articular injection of Betnovate Scalp Application is well tolerated in the joint and periarticular tissues.

Recommended doses for intra-articular injection are: Large joints (knee, hip, shoulder): 1-2 mL; medium joints (elbow, wrist, ankle): 0.5-1 mL; small joints (foot, hand chest): 0.25-0.5 mL.

Dermatologic conditions may respond to intralesional administration of Betnovate Scalp Application injection. Response of some lesions not treated directly may be due to a slight systemic effect of the drug. In intralesional treatment, an intradermal dosage of 0.2 mL/cm2 of Betnovate Scalp Application injection evenly injected with a tuberculin syringe and a 26-gauge needle is recommended. The total amount of Betnovate Scalp Application injected at all sites each week should not exceed 1 mL.

Betnovate Scalp Application injection may be used effectively in disorders of the foot that are responsive to corticosteroid therapy. Bursitis under heloma durum may be controlled with 2 successive injections of 0.25 mL each. In some conditions eg, hallux rigidus, digiti quinti varus and acute gouty arthritis, onset of relief may be rapid.

A tuberculin syringe with a 25-gauge needle is suitable for most injections. Recommended doses at intervals of approximately 1 week: Bursitis under heloma durum or molle 0.25-0.5 mL; bursitis under calcaneal spur 0.5 mL; bursitis over hallux rigidus 0.5 mL; Bursitis over digiti quinti; varus 0.5 mL; synovial cyst 0.25-0.5 mL; Morton's neuralgia (metatarsalgia) 0.25-0.5 mL; tenosynovitis 0.5 mL; periostitis of cuboid 0.5 mL; acute gouty arthritis 0.5-1 mL.

After a favorable response is obtained, the proper maintenance dosage should be determined by decreasing the initial dose in small decrements at appropriate time intervals until the lowest dose which will maintain an adequate clinical response is determined.

Exposure of the patient to stressful situations unrelated to the existing disease may necessitate an increased dose of Betnovate Scalp Application injection. If the drug is to be discontinued after long-term therapy, the dose should be decreased gradually.

What other drugs will affect Betnovate Scalp Application?

There are many other medicines that can interact with steroids. Below is only a partial list of these medicines:

This list is not complete and there may be other drugs that can interact with Betnovate Scalp Application. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Betnovate Scalp Application interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Betnovate Scalp Application, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Concurrent use of phenobarbital, phenytoin, rifampin or ephedrine may enhance the metabolism of corticosteroids, reducing their therapeutic effects.

Patients receiving both a corticosteroid and an estrogen should be observed for excessive corticosteroid effects.

Concurrent use of corticosteroids with potassium-depleting diuretics may enhance hypokalemia. Concurrent use of corticosteroids with cardiac glycosides may enhance the possibility of arrhythmias or digitalis toxicity associated with hypokalemia. Corticosteroids may enhance the potassium depletion caused by amphotericin B. In all patients taking any of these drug therapy combinations, serum electrolyte determinations, particularly potassium levels, should be monitored closely.

Concurrent use of corticosteroids with coumarin-type anticoagulants may increase or decrease the anticoagulant effects, possibly requiring adjustment in dosage.

Combined effects of nonsteroidal anti-inflammatory drugs or alcohol with glucocorticosteroids may result in an increased occurrence or increased severity of gastrointestinal ulceration.

Corticosteroids may decrease blood salicylate concentrations. Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Dosage adjustments of an antidiabetic drug may be necessary when corticosteroids are given to diabetics.

Concomitant glucocorticosteroid therapy may inhibit the response to somatotropin. Doses of Betnovate Scalp Application in excess of 300-450 mcg (0.3-0.45 mg)/m2 of body surface per day should be avoided during administration of somatotropin.

Laboratory Tests: Corticosteroids may affect the nitro-blue tetrazolium test for bacterial infection and produce false-negative results.


sponsored

References

  1. DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "9842X06Q6M: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Anti-Asthmatic Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Betnovate Scalp Application are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Betnovate Scalp Application. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


2 consumers reported doses

What doses of Betnovate Scalp Application drug you have used?
The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Betnovate Scalp Application drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
Users%
51-100mg2
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 8 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved